Skip to main content
. 2023 May 26;14:1194712. doi: 10.3389/fphar.2023.1194712

FIGURE 1.

FIGURE 1

Kaplen–Meier (KM). The survival without molecular relapse is shown in CML patients’ scoring, at the time of TKI discontinuation, “positive” for both CD26+LSCs and BCR::ABL1 copies (i.e., double positive), negative for both CD26+LSCs and BCR::ABL1 copies (i.e., double negative), and “discordant” with either way positive only for CD26+LSCs or BCR::ABL1 (i.e., discordant). In grey is reported the global CML patients’ survival without molecular relapse.